Q4 2025 earnings call recap: revenue growth, 2026 guidance cut to 8%, sales rebuild risks, and key catalysts—read now.

Barinthus Biotherapeutics plc has announced its strategic transformation focusing on immunology and inflammatory diseases, highlighting its promising immunotherapy VTP-1000 for celiac disease, which ...

As Canadian consumer’s needs and expectations continue to evolve, the ability to deliver products and services that enhance the customer’s experience, whether it be through convenience or speed has ...